The discovery of MFSD2A and LPC-mediated transport of EPA and DHA is a major scientific breakthrough with widespread implications and exciting potential clinical application areas. LYSOVETA™ by Aker BioMarine is the first LPC-EPA/DHA composition offered at scale, and for free, to the research community. We invite you to explore the original published research and to contact us for future collaboration opportunities.
Aker BioMarine is currently actively encouraging increased research and development activity in the LPC-EPA/DHA space. In particular, topics relating to brain and eye health at any stage of the human lifespan are welcome. Please contact us for more information on collaboration opportunities.